Imunon, Inc. Q4 FY2024 earnings call

• In July 2024, Imunon announced positive results from the Phase 2 OVATION 2 study for Imunon-001 in women with newly diagnosed advanced ovarian cancer.
• The Phase 2 data supports moving to a pivotal Phase 3 study, which is on track to initiate in Q1 2025, with FDA agreement.
• Updated overall survival data from OVATION 2 showed continued improvement, with median overall survival increasing from 11 months to 13 months in the intent-to-treat population.
• The TheraPlus technology confines IL-12 to the local tumor area, providing a strong safety profile.
• The MRD study in partnership with Breakthrough Cancer Foundation is enrolling patients, with preliminary results expected later in 2025.
• Cash management efforts to conserve cash, with cash runway extending into Q2 2025, and pursuing value-added financing and partnerships.
• Plasmin technology showed positive results in a Phase 1 COVID-19 vaccine trial, with persistent immunogenicity and favorable safety profile.

There is no detailed breakdown of product segments by revenue contribution as the transcript focuses on the Imunon-001 product and related trials. Financials mentioned are overall company results, but no product segment-specific performance.

• Plan to initiate the Phase 3 OVATION 3 study in Q1 2025.
• Goal to enroll 35 patients in the MRD combination study this year.
• Expect preliminary results from the MRD study later in 2025.
• Aim to secure financing and partnerships to support clinical timelines.

• Uncertainty in clinical trial outcomes, including whether Phase 3 results will replicate Phase 2 success.
• Market conditions and potential cash crunch issues, with cash runway extending into Q2 2025.
• Regulatory risks related to FDA approval processes and potential delays.

Q: Discuss the COVID booster neutralizing antibody data in the context of approved mRNA vaccines on the PB1.5 variant and prior COVID-19 infection.

A: Khursheed Anwer mentioned neutralizing antibody response levels are on par with mRNA vaccines, and subjects had prior infection/vaccination.

Q: Updated strategy for Phase 3 ovarian cancer study and trial design.

A: Protocol similar to OVATION 2, 500-patient study with overall survival as primary endpoints in HR deficient and intent-to-treat populations.

Q: Possibility of accelerated approval for Imunon-001.

A: Strength of evidence in subgroups, ongoing data maturation, and Phase 3 study underway could lead to accelerated approval.

Q: Partnership environment and cash crunch impact.

A: Successful meetings with investors, but tough market conditions; OVATION 2 data and FDA support are advantages.

Q: Impressive data that led Douglas Fowler to join Imunon.

A: OVATION 2's overall survival benefit, well-tolerated drug with no safety concerns, and potential to reset ovarian cancer standard of care.

Q: Enrollment in MRD study and acceleration drivers.

A: More sites coming on board, reengagement of previously affected sites, goal to enroll 35 patients this year.

Q: Durability of protection in Imunon-101 vaccine.

A: Assessed in naive environments, preclinical data suggests differentiation from mRNA vaccines, need for further study in naive models.